Traws Pharma, Inc.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for cancer and other diseases, currently funded through equity offerings and warrant exercises rather than product revenue.
Business. Traws Pharma, Inc. (Nasdaq: TRAW) is a biotechnology and life-science tools company headquartered in the United States. The firm operates within the Health Care sector, focusing on the development and commercialization of biotechnology products. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Its primary listing is on the Nasdaq stock exchange under the ticker symbol TRAW.
Analyst recommendations
2 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Traws Pharma, Inc. (Nasdaq: TRAW) is a biotechnology and life-science tools company headquartered in the United States. The firm operates within the Health Care sector, focusing on the development and commercialization of biotechnology products. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Its primary listing is on the Nasdaq stock exchange under the ticker symbol TRAW.
Traws Pharma maintains a negative equity position of -$5.3 million against total liabilities of $13.5 million, resulting in a debt-to-equity ratio of -0.0 and a return on equity of -1.73. The balance sheet holds $20.6 million in cash and equivalents, providing a liquidity buffer despite a current ratio of 0.43, which indicates current liabilities exceed current assets. The company generated negative operating cash flow of -$2.6 million in Q1 2026, offset partially by $1.9 million in financing proceeds from at-the-market offerings. The diluted share count of 10.6 million exceeds the basic count of 10.2 million, reflecting the impact of warrants and convertible instruments on the capital structure.
Profitability remains negative, with a net loss of $7.1 million and operating income of -$6.9 million in the latest quarter. The company reports a return on assets of 1.12, driven by the negative equity base rather than operational efficiency. Valuation metrics are distorted by the lack of earnings and revenue, with a price-to-earnings ratio of 0.51 and an EV/EBITDA of 0.89. The negative EV/Revenue of -5.69 underscores the pre-revenue status of the business. These figures contrast sharply with profitable industry peers, highlighting the speculative nature of the investment thesis.
The company operates as a single reportable segment, with no disclosed geographic revenue concentration due to the absence of commercial sales. Research and development activities are conducted domestically and internationally, with related-party transactions noted with entities such as Chemdiv Inc. and Viriom. The lack of segment diversification means all operational risk is concentrated in the success of its core pipeline programs.
Growth trajectory is defined by capital raising rather than top-line expansion. Revenue is effectively zero, with historical periods showing no commercial sales. The share count has expanded significantly, from 3.65 million in early 2024 to 10.16 million in Q1 2026, driven by private placements, warrant exercises, and at-the-market offerings. This dilution is a primary mechanism for sustaining operations in the absence of product revenue.
Risk assessment flags high liquidity and dilution risks. Filings reference going-concern or substantial-doubt language, indicating uncertainty about the company's ability to continue as a going concern without further financing. The current ratio of 0.43 suggests potential short-term liquidity constraints, although the cash balance provides a temporary buffer. The high dilution risk is exacerbated by the large number of outstanding warrants and options, which could further erode shareholder value upon exercise.
Recent events include a Nasdaq listing deficiency notice, with the stock closing below $1.00 for 34 consecutive days, triggering a cure period with a deadline of January 28, 2027. The company completed an April 2026 financing involving common stock warrants and milestone-based warrants. Analyst estimates show a mean price target of $1.00, with a hold recommendation, reflecting cautious sentiment. Management signals include consideration of accelerated share repurchases, though this is likely constrained by current liquidity conditions.
- Negative equity of -$5.3 million and a current ratio of 0.43 signal significant balance sheet stress, despite $20.6 million in cash.
- High dilution risk is evident from the 10.6 million diluted shares versus 10.2 million basic shares, driven by warrants and convertible instruments.
- Nasdaq listing deficiency requires a cure by January 2027, with the stock trading at $0.44, well below the $1.00 minimum bid price.
- No commercial revenue exists; the company relies entirely on equity financing to fund R&D and operations.
- Going-concern language in filings underscores the uncertainty of long-term viability without successful clinical outcomes or further capital raises.
Bull / Bear case
Generated · model-assistedNet margin of 3.29% ranks in the top quartile, significantly outperforming the cohort median of -2.67%.
Return on invested capital stands at 3.37%, indicating positive value generation despite negative equity metrics.
Return on assets of 1.12% suggests efficient asset utilization relative to the company's total asset base.
High dilution and liquidity risks are explicitly flagged, threatening shareholder value and operational continuity.
Current ratio of 0.72 indicates severe short-term liquidity constraints, falling well below the safe threshold of 1.0.
Operating margin of -6.41% underperforms the cohort median of -4.81%, reflecting weaker core operational efficiency.
Return on equity of -1.73% places the company in the bottom quartile of its biotechnology peer group.
In focus — financials by report
Operating income -$6.9M.
- ▍Operating income -$6.9M
Revenue $2.8M; Operating income -$10.5M.
- ▍Revenue $2.8M
- ▍Operating income -$10.5M
- ▍Net margin 595.4%
Revenue $2.8M; Operating income -$6.5M.
- ▍Revenue $2.8M
- ▍Operating income -$6.5M
- ▍Net margin 737.5%
Revenue $2.8M; Operating income -$17.9M.
- ▍Revenue $2.8M
- ▍Operating income -$17.9M
- ▍Net margin 328.7%
Revenue $226.0k; Operating income -$142.4M.
- ▍Revenue $226.0k
- ▍Operating income -$142.4M
- ▍Net margin -73682.7%
Revenue $226.0k; Operating income -$20.3M.
- ▍Revenue $226.0k
- ▍Operating income -$20.3M
- ▍Net margin -8384.1%
Revenue $226.0k; Operating income -$20.3M.
- ▍Revenue $226.0k
- ▍Operating income -$20.3M
- ▍Net margin -8384.1%
Revenue $226.0k; Operating income -$19.6M.
- ▍Revenue $226.0k
- ▍Operating income -$19.6M
- ▍Net margin -8391.2%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,42 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -21,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Diluted share count is moderately above the basic share count.
- Current liabilities exceed current assets.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- 10% owner · Series B Warrants (right to buy) → Common StockAcquired 597 729 @ $1,67purchase · 2026-04-16
- 10% owner · Series C Warrants (right to buy) → Common StockAcquired 1 793 187 @ $1,67purchase · 2026-04-16
- 10% owner · Series A Warrants (right to buy) → Common StockAcquired 597 729 @ $1,67purchase · 2026-04-16
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 104 544 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 31 258 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 231 336 @ $1,60grant · 2026-03-08
- Chief Science Officer Virology · Stock Option (right to buy) → Common StockAcquired 118 367 @ $1,60grant · 2026-03-08
- Director, Chief Operating Officer · Stock Option (right to buy) → Common StockAcquired 96 899 @ $1,60grant · 2026-03-08
- Director · Stock Option (right to buy) → Common StockAcquired 33 435 @ $1,60grant · 2026-03-08
- Chief Medical Officer · Stock Option (right to buy) → Common StockAcquired 108 854 @ $1,60grant · 2026-03-08
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 61 571 @ $2,33grant · 2025-12-12
- Chief Medical Officer · Stock Option (right to purchase) → Common StockAcquired 65 676 @ $2,33grant · 2025-12-12
- Director, Chief Operating Officer · Stock Option (right to purchase) → Common StockAcquired 65 676 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 16 234 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 19 496 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 24 629 @ $2,33grant · 2025-12-12
- Director, Chief Executive Officer · Stock Option (right to purchase) → Common StockAcquired 147 771 @ $2,33grant · 2025-12-12
- Chief Science Officer Virology · Stock Option (right to purchase) → Common StockAcquired 73 886 @ $2,33grant · 2025-12-12
- Director · Stock Option (right to purchase) → Common StockAcquired 12 770 @ $2,31grant · 2025-11-21
- Director, Chief Operating Officer · Stock Option (right to purchase) → Common StockAcquired 22 435 @ $3,01grant · 2025-10-12
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Traws Pharma, Inc. company facts · 2026-08-03
- Traws Pharma, Inc. 10-Q 2026-05-15 · 2026-08-03
- Traws Pharma, Inc. 10-K 2026-04-15 · 2026-08-03
- Traws Pharma, Inc. 10-Q 2025-11-13 · 2026-08-03
- Traws Pharma, Inc. 10-Q 2025-08-14 · 2026-08-03
- ha_price_listing fired on TRAW · 2026-08-03
- Traws Pharma Inc Market data — analyst estimates · 2026-08-03
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Iain D. DukesExecutive Chairman of the Board
Insider activity
- 10% owner · Common StockBought 597 729 @ $1,67$998K · 2026-04-16
- Chief Science Officer Virology · Common StockOther 18 471 · 2025-12-12
- Chief Medical Officer · Common StockOther 16 419 · 2025-12-12
- Director, Chief Operating Officer · Common StockOther 16 419 · 2025-12-12
- Chief Financial Officer · Common StockOther 15 393 · 2025-12-12
- Director · Common StockOther 4 058 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director · Common StockOther 4 874 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director · Common StockOther 6 157 · 2025-12-12
- Director, Chief Executive Officer · Common StockOther 36 943 · 2025-12-12
Short positioning
Geographic breakdown
Intel & risk
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
- Company share pct— → —medium
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1,134.5%Derived (calculated)
- Net margin (FY 2025-12-31): 328.7%Derived (calculated)
- Return on assets (FY 2025-12-31): 86.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.72xDerived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 102.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 102.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 105.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 39.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 87.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -57.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -80.1%Derived (calculated)
- Operating cash flow (annual): USD -18.18MSEC XBRL filing
- Total assets (annual): USD 10.62MSEC XBRL filing
- Pre-tax income (annual): USD 9.17MSEC XBRL filing
- Total liabilities (annual): USD 11.25MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
- Operating income (annual): USD -17.88MSEC XBRL filing
- Revenue (annual): USD 2.79MSEC XBRL filing
- Shares outstanding (annual): 9.07MSEC XBRL filing
- Current liabilities (annual): USD 11.15MSEC XBRL filing
- Current assets (annual): USD 7.98MSEC XBRL filing
- Total operating expenses (annual): USD 20.66MSEC XBRL filing
- Net income (annual): USD 9.17MSEC XBRL filing